1898 related articles for article (PubMed ID: 28076709)
21. Therapeutic Options for Neuroendocrine Tumors: A Systematic Review and Network Meta-analysis.
Kaderli RM; Spanjol M; Kollár A; Bütikofer L; Gloy V; Dumont RA; Seiler CA; Christ ER; Radojewski P; Briel M; Walter MA
JAMA Oncol; 2019 Apr; 5(4):480-489. PubMed ID: 30763436
[TBL] [Abstract][Full Text] [Related]
22. The radiosensitizer Onalespib increases complete remission in
Lundsten S; Spiegelberg D; Raval NR; Nestor M
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):980-990. PubMed ID: 31912256
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Nausea and Vomiting Associated With Amino Acid Formulations Coinfused With Peptide Receptor Radionuclide Therapy: Commercial Parenteral Nutrition Formulas Versus Compounded Arginine/Lysine.
Al-Toubah T; Sikaria D; Jesurajan J; Bottiglieri S; Smith J; Pellé E; Hutchinson T; Strosberg J; El-Haddad G
Pancreas; 2021 Apr; 50(4):513-515. PubMed ID: 33939662
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of Everolimus Combined with
Aljubran A; Badran A; Alrowaily M; Raef H; Alzahrani AM; Almuhaideb A; Almanea H; El-Dali A; Tuli M; Bazarbashi S
Cancer Biother Radiopharm; 2024 Mar; 39(2):164-168. PubMed ID: 36342790
[No Abstract] [Full Text] [Related]
25. 177 Lu-DOTATATE Salvage Therapy in Rapidly Progressing Neuroendocrine Tumor With Poor Performance Status.
Aggarwal P; Kumar A; Sood A; Walia R; Bhadada SK; Mittal BR
Clin Nucl Med; 2024 Jun; 49(6):561-563. PubMed ID: 38498693
[TBL] [Abstract][Full Text] [Related]
26. Extravasation After [ 177 Lu]Lu-HA-DOTATATE Therapy.
de Vries-Huizing DMV; Cheung ZJ; Hendrikx JJMA; Donswijk ML; Versleijen MWJ
Clin Nucl Med; 2024 May; 49(5):454-456. PubMed ID: 38465961
[TBL] [Abstract][Full Text] [Related]
27. Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET.
Singh S; Ferone D; Capdevila J; Chan JA; de Herder WW; Halperin D; Mailman J; Hellström L; Liedman H; Svedberg A; Tiberg F
Trials; 2024 Jan; 25(1):58. PubMed ID: 38229199
[TBL] [Abstract][Full Text] [Related]
28. Long-term clinical outcomes of [
Iqbal S; Zhuang E; Raj M; Bahary N; Monga DK
Front Oncol; 2024; 14():1393317. PubMed ID: 38817893
[TBL] [Abstract][Full Text] [Related]
29. Sequencing of Somatostatin-Receptor-Based Therapies in Neuroendocrine Tumor Patients.
Strosberg JR; Al-Toubah T; El-Haddad G; Reidy Lagunes D; Bodei L
J Nucl Med; 2024 Mar; 65(3):340-348. PubMed ID: 38238038
[TBL] [Abstract][Full Text] [Related]
30. Large cardiac metastasis from pancreatic neuroendocrine tumor and response to peptide receptor radionuclide therapy with
Parghane RV; Basu S
J Nucl Cardiol; 2020 Feb; 27(1):340-341. PubMed ID: 30151794
[No Abstract] [Full Text] [Related]
31. Letter to the editor regarding "The effect of long-acting somatostatin analogs on the uptake of [
Wang R; Guo L; Shen G
Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):180-182. PubMed ID: 37561142
[No Abstract] [Full Text] [Related]
32. Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network.
Brizzi MP; Berruti A; Ferrero A; Milanesi E; Volante M; Castiglione F; Birocco N; Bombaci S; Perroni D; Ferretti B; Alabiso O; Ciuffreda L; Bertetto O; Papotti M; Dogliotti L
BMC Cancer; 2009 Nov; 9():388. PubMed ID: 19886987
[TBL] [Abstract][Full Text] [Related]
33. E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors.
Lubner S; Feng Y; Mulcahy M; O'Dwyer P; Giang GY; Hinshaw JL; Deming D; Klein L; Teitelbaum U; Payne J; Engstrom P; Stella P; Meropol N; Benson A
Oncologist; 2018 Sep; 23(9):1006-e104. PubMed ID: 29853660
[TBL] [Abstract][Full Text] [Related]
34. Peptide Receptor Radionuclide Therapy Performed Shortly After Administration of Long-Acting Octreotide.
Low HC; Tay YS; Ong SYK; Tham WY; Yan SX
Clin Nucl Med; 2023 Dec; 48(12):1086-1088. PubMed ID: 37844418
[TBL] [Abstract][Full Text] [Related]
35. p53 stabilisation potentiates [
Berglund H; Salomonsson SL; Mohajershojai T; Gago FJF; Lane DP; Nestor M
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):768-778. PubMed ID: 37823909
[TBL] [Abstract][Full Text] [Related]
36. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
Love C; Desai NB; Abraham T; Banks KP; Bodei L; Boike T; Brown RKJ; Bushnell DL; DeBlanche LE; Dominello MM; Francis T; Grady EC; Hobbs RF; Hope TA; Kempf JS; Pryma DA; Rule W; Savir-Baruch B; Sethi I; Subramaniam RM; Xiao Y; Schechter NR
Am J Clin Oncol; 2022 Jun; 45(6):233-242. PubMed ID: 35507413
[TBL] [Abstract][Full Text] [Related]
37. Clinical impact of unsuccessful subcutaneous administration of octreotide LAR instead of intramuscular administration in patients with metastatic gastroenteropancreatic neuroendocrine tumors.
Krishnan T; Safro M; Furlanetto DM; Gill S; Solar Vasconcelos JP; Stuart HC; Martineau P; Loree JM
J Neuroendocrinol; 2024 Jan; 36(1):e13360. PubMed ID: 38088132
[TBL] [Abstract][Full Text] [Related]
38. Initial Findings on the Use of [
Demirci E; Alan Selçuk N; Beydağı G; Ocak M; Toklu T; Akçay K; Kabasakal L
Mol Imaging Radionucl Ther; 2023 Oct; 32(3):226-232. PubMed ID: 37870290
[TBL] [Abstract][Full Text] [Related]
39.
Donzé C; Rubira L; Santoro L; Viarasakd M; Kotzki PO; Deshayes E; Fersing C
Eur J Hosp Pharm; 2024 Apr; 31(3):207-211. PubMed ID: 36100369
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]